About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

UNKNOWNPhase 2

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Nivolumab After Cyclophosphamide and Doxorubicin(CA) Induction Therapy in Previously Treated Advanced Non-squamous Cell Non-small Cell Lung Cancer With PD-L1<10%

NCT03808480•National Cancer Center, Korea

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non-small Cell Lung Cancer

Interventions

CA and Nivolumab

Locations

1

South Korea

Locations (1)

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Key Dates

Start Date

January 23, 2019

Primary Completion Date

May 31, 2022

Completion Date

May 31, 2022

Last Updated

April 6, 2022

Related Studies

RECRUITINGPhase 1/2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817

Non-Small Cell Lung CancerNSCLC+1 more

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280

Non-small Cell CarcinomaNon-Small Cell Lung Cancer Metastatic+1 more

RECRUITINGPhase 3

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827

Non-small Cell Lung Cancer

RECRUITINGPhase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401

Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung+1 more

RECRUITINGPhase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular Carcinoma+3 more

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808

High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)+1 more

View all related studies

Contacts

Ji-youn Han, Ph.D

CONTACT

82-31-920-1210 jymama@ncc.re.kr

Sehee Oh

CONTACT

82-31-920-0398 oshee97@ncc.re.kr

Sponsors

Lead Sponsor

National Cancer Center, Korea

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2022Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions